Your browser doesn't support javascript.
loading
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Gakis, G; Morgan, T M; Daneshmand, S; Keegan, K A; Todenhöfer, T; Mischinger, J; Schubert, T; Zaid, H B; Hrbacek, J; Ali-El-Dein, B; Clayman, R H; Galland, S; Olugbade, K; Rink, M; Fritsche, H-M; Burger, M; Chang, S S; Babjuk, M; Thalmann, G N; Stenzl, A; Efstathiou, J A.
Afiliação
  • Gakis G; Department of Urology, University of Tuebingen, Tuebingen, Germany georgios.gakis@googlemail.com.
  • Morgan TM; Department of Urology, University of Michigan, Ann Arbor, USA.
  • Daneshmand S; Institute of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles.
  • Keegan KA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
  • Todenhöfer T; Department of Urology, University of Tuebingen, Tuebingen, Germany.
  • Mischinger J; Department of Urology, University of Tuebingen, Tuebingen, Germany.
  • Schubert T; Department of Urology, University of Tuebingen, Tuebingen, Germany.
  • Zaid HB; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
  • Hrbacek J; 2nd Medical School, Department of Urology, Charles University, Prague, Czech Republic.
  • Ali-El-Dein B; Urology and Nephrology Center, Mansoura Clinic, Mansoura, Egypt.
  • Clayman RH; Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Galland S; Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Olugbade K; Department of Urology, University of Michigan, Ann Arbor, USA.
  • Rink M; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg.
  • Fritsche HM; Department of Urology, University Hospital Regensburg, Regensburg, Germany.
  • Burger M; Department of Urology, University Hospital Regensburg, Regensburg, Germany.
  • Chang SS; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA.
  • Babjuk M; 2nd Medical School, Department of Urology, Charles University, Prague, Czech Republic.
  • Thalmann GN; Department of Urology, University Hospital Bern, Bern, Switzerland.
  • Stenzl A; Department of Urology, University of Tuebingen, Tuebingen, Germany.
  • Efstathiou JA; Department of Radiooncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Ann Oncol ; 26(8): 1754-9, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25969370
ABSTRACT

BACKGROUND:

To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). PATIENTS AND

METHODS:

A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for PUC in 10 referral centers between 1993 and 2012. Kaplan-Meier analysis with log-rank testing was used to investigate the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean 32 months; interquartile range 5-48).

RESULTS:

Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy (ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery (P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of neoadjuvant treatment was significantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS (P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005).

CONCLUSION:

In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without ACH.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uretra / Neoplasias Uretrais / Carcinoma de Células Escamosas / Carcinoma de Células de Transição / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Terapia Neoadjuvante / Quimiorradioterapia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uretra / Neoplasias Uretrais / Carcinoma de Células Escamosas / Carcinoma de Células de Transição / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Terapia Neoadjuvante / Quimiorradioterapia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article